IL17A and inflammatory bowel disease: Several treatments, such as the use of TNF-α inhibitors, seek to suppress these immune regulators in IBD, which is characterized as the chronic relapse of inflammatory disorders of the GI tract associated with an increased expression of IFNγ, IL-17A and IL-22 in inflamed mucosa [30], [31].